Hero image

Myelofibrosis (MF) & anaemia

Anaemia in myelofibrosis (MF) may result from disruption in normal erythropoiesis due to a proinflammatory environment, fibrotic bone marrow, increased red blood cell (RBC) turnover and splenic sequestration of RBC.1

Approximately 44% (88/200) of MF patients are anaemic at diagnosis2 and approximately 58% (158/274) of MF patients are anaemic within 1 year of diagnosis.3

Survival is negatively impacted in MF patients with anaemia*4

Survival in MF patients with anaemia

Adapted from Nicolosi et al. 20184

No anaemia: Normal Hb levels (reference ranges for Hb were 13.5–17.5 g/dL for men and 12.0–15.5 g/dL for women); n=159/N=1,109.4
Moderate anaemia: Hb ≥ 8 to <10 g/dL; n=159/N=1,109. HR: 2.1 (95% CI: 1.6–2.8).4
Severe anaemia: Hb <8 g/dL; n=407/N=1,109. HR: 3.4 (95% CI: 2.7–4.3).4
*Based on a retrospective observational study of 1,109 consecutive patients with primary MF seen at the Mayo Clinic, Rochester, Minnesota, USA.
Reference Hb ranges at this institution were 13.5–17.5 g/dL for men and 12.0–15.5 g/dL for women.4


CI, confidence interval; Hb, haemoglobin; HR, hazard ratio; MF, myelofibrosis

Anaemia-related factors impact OS in MF5,6

Transfusion dependency is a predictor of poor survival in MF5

Transfusion dependency and survival

Adapted from Elena et al. 20115

Elevated hepcidin is a predictor of poor survival in MF6

Elevated hepcidin and survival

Adapted from Pardanani et al. 20136

*Transfusion dependency was defined as the onset of regular transfusion requirement to correct anaemia (at least one unit per month).5
**Based on a study conducted on 288 consecutive patients with primary MF diagnosed between 1975 and 2009 at the Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy. Time-dependent statistical analysis was carried out on 220 patients regularly followed for the whole course of the disease (at least three visits a year).5
†Elevated circulating hepcidin and ferritin were defined as >91,604 pg/mL (>3 standard deviations above the mean) and >500 μg/L, respectively.6
‡Based on a study of 203 consecutive primary MF patients at the time of first referral.6


CI, confidence interval; HR, hazard ratio; MF, myelofibrosis; OS, overall survival

Indication

Omjjara ▼ (momelotinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (MF), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are:
1. Janus Kinase (JAK) inhibitor naïve
or
2. Have been treated with ruxolitinib.7

References

  1. Naymagon L;Hemasphere;2017;1;1-9.
  2. Mead AJ et al. Ther Adv Hematol. 2022;13:1-15.
  3. Passamonti F, Clin Rev Onc/Hem; 2022; 180:1040-8428
  4. Nicolosi M et al. Leukemia. 2018;32;1254-1258.
  5. Elena C et al. Haematologica. 2011;96:167-170.
  6. Pardanani A et al. Am J Hematol. 2013;88:312-316.
  7. UK OMJJARA SmPC.

 

▶︎ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GSK on 0800 221 441, via email: uksafety@gsk.com or at https://gsk.public.reportum.com/

November 2026 | PM-GB-MML-WCNT-260012 (V1.0)